Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3, Observer-Blind, Immuno-bridging, and Broadening Study of a Whole, Inactivated Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Vaccine (BBV152) in Healthy Adults

NCT05258669 is registered in ClinicalTrials.gov with Ocugen as lead sponsor.

NCT NCT05258669
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05258669 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3, Observer-Blind, Immuno-bridging, and Broadening Study of a Whole, Inactivated Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Vaccine (BBV152) in Healthy Adults
Lead sponsor
Ocugen
Phase
Phase 2/3
Overall status
Unknown status
Start date
February 20, 2022
Completion date
October 31, 2023
Enrollment
400 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19